MariMed Stock

MariMed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of MariMed (MRMD) as of Aug 7, 2026 is -41.86 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 47.22 % — a change of -188.65% (lower).

FCF Conversion

-41.86 %

YoY

-188.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of MariMed is 2026 -41.86 % . FCF Conversion Rate (FCF/EBITDA) of MariMed was 2025 47.22 % . It decreases by -188.65% lower compared to the previous year.
Access this data via the Eulerpool API

MariMed Stock analysis

What does MariMed do? Marimed Inc is a leading company in the development of medical cannabis and hemp products. The company was founded in 2011 and has since made a name for itself through its innovative products and its focus on research and development of plant-based products. Marimed Inc's business model is based on the research, development, and marketing of cannabis products. The company focuses on the development of medical cannabis products as well as the trade in hemp products. The product range includes oils, tinctures, capsules, vaporizers, and other electronic devices. The various divisions of Marimed Inc include research and development, marketing, distribution, and licensing of medical cannabis. As a fully integrated company, Marimed Inc has its own cultivation, processing, and shipping infrastructure to ensure smooth delivery of high-quality cannabis products. Another focus of the company is research, which focuses on the development of new cannabinoid compounds for the treatment of diseases such as epilepsy, inflammation, and arthritis. Thanks to this research, new products are constantly being developed to guarantee customers high effectiveness and quality. An important factor for the success of Marimed Inc is its responsibility towards the environment and society. The company places great value on working sustainably and environmentally friendly, as well as convincing society of the benefits of medical cannabis products. Among the products offered by Marimed Inc are the products of the Betty's Eddies brand. These products are specifically designed for patients suffering from ailments such as anxiety, insomnia, and pain. Betty's Eddies guarantees high effectiveness and a pleasant taste with its products. Another product offered by Marimed Inc is the MariCann Vaporizer System. The vaporizer is a fast and easy way to consume medical cannabis without burdening the body. The device is suitable for both medical cannabis patients and recreational users. Marimed Inc is a company that is always looking for new solutions and innovations to offer customers the best possible quality. The company is heavily involved in research and development to improve the quality of its products and promote the positive effects of medical cannabis on society. Marimed Inc is a company that can be trusted when it comes to medical cannabis and other hemp products. MariMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MariMed stock

FCF Conversion Rate (FCF/EBITDA) of MariMed is -41.86 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of MariMed changed from 47.22 % to -41.86 %, representing a -188.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) MariMed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s MariMed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — MariMed

All Key Metrics — MariMed